Indivior (INDV)

Executive Summary

Indivior is a global pharmaceutical leader in addiction medicine, specializing in treatments for opioid use disorder (OUD) and serious mental illnesses. The company's portfolio includes market-leading products such as Sublocade (buprenorphine extended-release injection) and Perseris (risperidone for schizophrenia). Indivior recently completed its redomiciliation from the UK to the US, aligning its corporate structure with its primary market and potentially improving operational efficiencies. As of mid-2026, Indivior holds a valuation of approximately $4.5 billion and has generated steady revenue from its OUD franchise. The company faces ongoing patent litigation with generic competitors, but its focus on long-acting injectables and novel formulations positions it to defend market share. Indivior's strong brand recognition and established relationships with addiction treatment providers underpin its competitive advantage, though the regulatory environment and reimbursement dynamics remain key risk factors.

Upcoming Catalysts (preview)

• H2 2026FDA approval of a new long-acting buprenorphine formulation for OUD65% success
• Q4 2026Resolution of patent litigation with generics protecting Sublocade exclusivity50% success
• 2027Positive Phase 3 data for a novel candidate targeting alcohol use disorder40% success